Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor
Brief Summary: To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1
B: Arm Label: RAD001 +BSC; Type: EXPERIMENTAL; Interventions: Drug: RAD001 | Arm Label: Placebo (plus BSC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): RAD001 +BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (plus BSC)
C: Arm Label: Lenvatinib 18 mg plus Everolimus 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Lenvatinib 20 mg plus Pembrolizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Arm Label: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg, Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Lenvatinib 18 mg plus Everolimus 5 mg | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib 20 mg plus Pembrolizumab 200 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib 50 mg
D: Arm Label: Arm A (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study | Arm Label: Arm B (bevacizumab and temsirolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Temsirolimus | Arm Label: Arm C (bevacizumab and sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm D (sorafenib tosylate and temsirolimus); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate, Drug: Temsirolimus | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm B (bevacizumab and temsirolimus), Arm D (sorafenib tosylate and temsirolimus)

Answer: B